AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tucker, S. P.
Right arrow Articles by Bryant, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tucker, S. P.
Right arrow Articles by Bryant, M. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 478-480, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance within Unselected Virus Populations In Vitro

Simon P. Tucker,* Thomas R. Stiebel Jr., Karen E. Potts,dagger Mary L. Smidt, and Martin L. BryantDagger

G. D. Searle, Searle Research and Development, St. Louis, Missouri 63198

Received 25 February 1997/Returned for modification 16 May 1997/Accepted 7 July 1997

The frequency of drug-resistant human immunodeficiency virus type 1 (HIV-1) variants in virus populations not previously exposed to drug was determined in vitro by using HIV-1RF and the protease inhibitor SC-55389A. Two variants with single mutations responsible for drug resistance (V82A and N88S) were quantifiably isolated after only one round of replication, yielding a crude frequency estimate of at least 1 SC-55389A-resistant variant per 3.5 × 105 wild-type infectious units.

* Corresponding author. Present address: Biota Holdings Limited, Level 4, 616 St Kilda Rd., Melbourne, Victoria 3004, Australia. Phone: 61 3 9529 2311. Fax: 61 3 9529 2261. E-mail: simon.t{at}biota.com.au.

dagger Present address: Agouron Pharmaceuticals, Inc., Research Laboratories, San Diego, Calif.

Dagger Present address: Aviron, Mountain View, Calif.

Antimicrobial Agents and Chemotherapy, February 1998, p. 478-480, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.